Establishing a New Platform to Investigate the Efficacy of Oncolytic Virotherapy in a Human Ex Vivo Peritoneal Carcinomatosis Model
J. Koch(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Ulrich M. Lauer(German Cancer Research Center), Annika Maaß(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Linus D. Kloker, Philipp Renner(Robert Bosch Hospital), Andrea Schenk(Universitätsklinikum Tübingen), Mary E. Carter, Julia Beil(German Cancer Research Center), Marc‐H. Dahlke(Robert Bosch Hospital), Dina Mönch(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Irina Smirnow, Tobias Leibold(Robert Bosch Hospital), Susanne Berchtold(University Children's Hospital Tübingen)
Cited by 3
Related Papers
Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate
|Transplant Immunology|2008|198
Urinary Biomarkers TIMP-2 and IGFBP7 Early Predict Acute Kidney Injury after Major Surgery
|PLoS ONE|2015|169
Mesenchymal Stem Cells Require a Sufficient, Ongoing Immune Response to Exert Their Immunosuppressive Function
|Transplantation Proceedings|2009|124
Liver surgery in cirrhosis and portal hypertension
|World Journal of Gastroenterology|2016|107
Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model
|Transplant Immunology|2011|92